Cyclophosphamide is widely used to treat severe manifestations of numerous autoimmune rheumatic diseases including systemic sclerosis. Based on recent data, immunological and inflammatory activation remain the primary therapeutic targets in systemic sclerosis. Other effective therapies targeting the fibrotic mechanisms have not been developed despite the increased understanding of the key pathogenic pathways. The two pivotal studies of cyclophosphamide in scleroderma-associated interstitial lung disease have rejuvenated interest in this chemotherapeutic agent in this disease. Although the studies suggest that the benefit is modest, identification of appropriate patients is central to management to harness its maximal potential clinical efficacy. This article provides a timely evaluation of the benefits and drawbacks of cyclophosphamide in systemic sclerosis

Cyclophosphamide as disease-modifying therapy for scleroderma: pros and cons / C. Chighizola, V.H. Ong, C.P. Denton. - In: INTERNATIONAL JOURNAL OF CLINICAL RHEUMATOLOGY. - ISSN 1758-4272. - 6:2(2011 Apr), pp. 219-230. [10.2217/ijr.10.112]

Cyclophosphamide as disease-modifying therapy for scleroderma: pros and cons

C. Chighizola;
2011

Abstract

Cyclophosphamide is widely used to treat severe manifestations of numerous autoimmune rheumatic diseases including systemic sclerosis. Based on recent data, immunological and inflammatory activation remain the primary therapeutic targets in systemic sclerosis. Other effective therapies targeting the fibrotic mechanisms have not been developed despite the increased understanding of the key pathogenic pathways. The two pivotal studies of cyclophosphamide in scleroderma-associated interstitial lung disease have rejuvenated interest in this chemotherapeutic agent in this disease. Although the studies suggest that the benefit is modest, identification of appropriate patients is central to management to harness its maximal potential clinical efficacy. This article provides a timely evaluation of the benefits and drawbacks of cyclophosphamide in systemic sclerosis
cyclophosphamide, systemic sclerosis, interstitial lung disease, haemorrhagic cystitis, Malignancy
Settore MED/16 - Reumatologia
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/254409
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 5
  • ???jsp.display-item.citation.isi??? ND
social impact